MedTrace Logo

Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus

NCT06673043 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-05-13

No results posted yet for this study

Summary

The Polish multicentre observational (non-interventional) study aiming to collect data on the characteristic of patients with systemic lupus erythematosus and clinical outcomes of anifrolumab administered in the scope of routine clinical practice.

Conditions

  • Lupus Erythematosus, Systemic

Interventions

DRUG

Anifrolumab

Anifrolumab 300 mg concentrate for solution for infusion

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-28
Primary Completion
2028-06-30
Completion
2028-06-30
FDA Drug
Yes

Countries

  • Poland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06673043 on ClinicalTrials.gov